A regression predictive model for QuantiFERON-TB Gold Plus

IGRA QuantiFERON-TB Gold immune suppression indeterminate results latent tuberculosis infection

Journal

SAGE open medicine
ISSN: 2050-3121
Titre abrégé: SAGE Open Med
Pays: England
ID NLM: 101624744

Informations de publication

Date de publication:
2024
Historique:
received: 15 05 2024
accepted: 09 08 2024
medline: 12 9 2024
pubmed: 12 9 2024
entrez: 12 9 2024
Statut: epublish

Résumé

Screening for latent tuberculosis infection using Interferon-Gamma Release Assays is a routine procedure prior to the initiation of anti-tumor necrosis factor (TNF) biotherapy or immunosuppressive therapy. However, indeterminate results are relatively frequent and are an obstacle to treatment initiation. The aim of this cross-sectional study was to estimate the frequency of indeterminate QuantiFERON-TB Gold Plus Whole blood samples from 712 patients being monitored for autoimmune diseases and candidates for anti-TNF biotherapy or switch of immunosuppressive therapy were used to screen for latent tuberculosis infection using the QuantiFERON-TB Gold Plus The QuantiFERON-TB Gold Plus Immunosuppressive therapy, lymphopenia, hypoalbuminemia, and kidney failure appeared to be risk factors for indeterminate QuantiFERON-TB Gold Plus

Sections du résumé

Background UNASSIGNED
Screening for latent tuberculosis infection using Interferon-Gamma Release Assays is a routine procedure prior to the initiation of anti-tumor necrosis factor (TNF) biotherapy or immunosuppressive therapy. However, indeterminate results are relatively frequent and are an obstacle to treatment initiation.
Aim UNASSIGNED
The aim of this cross-sectional study was to estimate the frequency of indeterminate QuantiFERON-TB Gold Plus
Methods UNASSIGNED
Whole blood samples from 712 patients being monitored for autoimmune diseases and candidates for anti-TNF biotherapy or switch of immunosuppressive therapy were used to screen for latent tuberculosis infection using the QuantiFERON-TB Gold Plus
Results UNASSIGNED
The QuantiFERON-TB Gold Plus
Conclusion UNASSIGNED
Immunosuppressive therapy, lymphopenia, hypoalbuminemia, and kidney failure appeared to be risk factors for indeterminate QuantiFERON-TB Gold Plus

Identifiants

DOI: 10.1177/20503121241279116 PMID: 39263635 PMC: PMC11388302
pubmed: 39263635
doi: 10.1177/20503121241279116
pii: 10.1177_20503121241279116
pmc: PMC11388302
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20503121241279116

Informations de copyright

© The Author(s) 2024.

Déclaration de conflit d'intérêts

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Rahma Bellagha (R)

Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.

Tarak Dhaouadi (T)

Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.
ORCID: 0000-0002-6376-0950

Awatef Riahi (A)

Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.

Wahiba Ben Rehouma (W)

Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.

Hajer Jedidi (H)

Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.

Leila Mouelhi (L)

Department of Gastro-Enterology, Charles Nicolle Hospital, Tunis, Tunisia.

Leila Abdelmoula (L)

Department of Rheumatology, Charles Nicolle Hospital, Tunis, Tunisia.

Taïeb Ben Abdallah (T)

Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.

Yousr Gorgi (Y)

Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.

Imen Sfar (I)

Research Laboratory in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.

Classifications MeSH